Collegium Pharmaceutical Inc (NASDAQ:COLL) has been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $29.40.
COLL has been the subject of several research analyst reports. BidaskClub lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 9th. Needham & Company LLC lifted their price objective on Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, December 7th. Finally, Jefferies Group lifted their price objective on Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th.
In related news, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the transaction, the insider now directly owns 32,651 shares in the company, valued at $622,654.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Longitude Capital Partners, Ll sold 1,000,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, December 8th. The shares were sold at an average price of $17.34, for a total value of $17,340,000.00. The disclosure for this sale can be found here. Insiders sold 1,046,928 shares of company stock valued at $18,422,317 in the last ninety days. 25.76% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Voya Investment Management LLC purchased a new position in Collegium Pharmaceutical during the second quarter valued at $125,000. Benjamin F. Edwards & Company Inc. lifted its position in Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares in the last quarter. Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at $176,000. Finally, JPMorgan Chase & Co. purchased a new position in Collegium Pharmaceutical during the third quarter valued at $192,000. Institutional investors own 89.28% of the company’s stock.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded up $0.54 on Friday, hitting $25.90. The company had a trading volume of 414,200 shares, compared to its average volume of 633,319. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $26.77. The company has a market capitalization of $844.67 and a price-to-earnings ratio of -8.73.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/20/collegium-pharmaceutical-inc-coll-receives-29-40-average-pt-from-analysts.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.